Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI

Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction Magnetic Resonance Imaging (MRI)

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06201351

Enrollment

Registered

2024-01-11

Start date

2024-01-01

Completion date

2026-09-30

Last updated

2024-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-grade Glioma

Keywords

adaptive radiotherapy, high-grade glioma, MRI image

Brief summary

The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.

Detailed description

To prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.The related factors causing this change are discussed.The relationship between changes and patient survival was analyzed.A predictive model was established to provide individualized adaptive radiotherapy for patients.

Interventions

DEVICEadaptive radiotherapy

MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Age ≥18 years old; 2. High-grade glioma was confirmed by pathology after surgery; 3. ECOG score 0-2 points; 4. Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy); 5. Baseline data available.

Exclusion criteria

1. The pathological diagnosis is not clear; 2. No synchronous chemotherapy/adjuvant chemotherapy < 6 cycles; 3. There are other malignant tumors; 4. Previously radiotherapy to the head; 5. Interruption of radiotherapy for more than 5 days; 6. Failure to collect baseline data.

Design outcomes

Primary

Measure	Time frame	Description
Homogeneity index	up to 2 weeks	HI: Homogeneity index. Dosimetric change
conformity index	up to 2 weeks	CI: conformity index. Dosimetric change
Anatomic change	up to 2 weeks	Dmax Volume

Secondary

Measure	Time frame	Description
progression-free survival (PFS)	assessed up to 12 months	progression-free survival

Countries

China

Contacts

Primary ContactPing Ai, MD

aip2023@163.com18980602055

Backup ContactShuangshuang He

hess9707@163.com18708178816

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026